DURHAM, N.C., Sept. 17 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. has posted a new Blog entry by company chairman and CEO, Chris Stern. In the blog, Stern answers questions posed by shareholders regarding the company's proposed 1-for-15 reverse stock split.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.
SOURCE Oxygen Biotherapeutics, Inc.
CONTACT: Abe Wischnia, Abe Wischnia & Associates, +1-619-795-2345, for
Oxygen Biotherapeutics, Inc.
Web site: http://www.oxybiomed.com/
